Blackstone has raised a new fund called Blackstone Life Sciences Yield (BXLS Yield), providing $1.6bn in additional capital for drug, device and diagnostic developers with late-stage assets. But while the $4.6bn Blackstone Life Sciences Fund V that closed in 2020 focused on product candidates in late-stage development, the new fund is targeting companies with approved products.
The Blackstone Life Sciences (BXLS) private investment platform exists to fill funding gaps in later stages of product development and the firm’s new fund aims to provide stability to companies seeking capital in a turbulent financial market
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?